IGC Pharma, Inc.
IGC Pharma, Inc. is a pharmaceutical company that generates revenue from the development and sale of pharmaceutical products, currently operating at a significant net loss while relying on equity issuances and debt to fund operations.
Business. IGC Pharma, Inc. (NYSE: IGC) is a pharmaceutical company engaged in the development and commercialization of drug products. The firm operates within the broader healthcare sector, focusing on pharmaceuticals and medical research activities. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level. IGC Pharma is headquartered in the United States and is primarily listed on the New York Stock Exchange.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
IGC Pharma, Inc. (IGC) has undergone a comprehensive revision of its AI-driven analytical profile, with significant updates to its business summary, narrative, and key takeaways. The most material change involves a 30.58% increase in the company's calculated market share percentage, which rose from approximately 4.51e-09 to 5.89e-09. This adjustment, alongside the removal of eight key takeaways and the addition of one, reflects a substantial recalibration of the firm's strategic positioning and operational outlook within the analysis framework. These modifications stem from a medium-severity update sourced from the "ha_light_thesis," which triggered a complete overhaul of the analytical conclusion and supporting narratives. The low similarity scores between the old and new narratives (0.041) and business summaries (0.103) indicate that the underlying assumptions or data inputs driving the analysis have shifted significantly, rather than representing minor incremental adjustments. Despite these analytical shifts, the fundamental structural metrics of IGC Pharma remain static. The company continues to operate with a single officer and maintains zero analyst coverage and no index memberships. Additionally, the shareholder base remains concentrated, with nine top holders identified, suggesting that the recent analytical changes have not yet translated into broader institutional engagement or structural corporate changes. The significance of these changes lies in the refined understanding of IGC's market position, even as its absolute market share remains negligible. The updated analysis provides a more current view of the company's business dynamics, which is critical for stakeholders monitoring a firm with limited public financial scrutiny. As the company continues to report through its standard regulatory filings, these analytical updates serve as the primary indicator of evolving internal or external perceptions of its value proposition.
Signals & dispatch
Composite-score breakdown
Synthesis
IGC Pharma, Inc. (NYSE: IGC) is a pharmaceutical company engaged in the development and commercialization of drug products. The firm operates within the broader healthcare sector, focusing on pharmaceuticals and medical research activities. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level. IGC Pharma is headquartered in the United States and is primarily listed on the New York Stock Exchange.
IGC Pharma operates with a fragile capital structure characterized by high liquidity risk and negative returns. The company reports a current ratio of 0.4, indicating that current liabilities of $3.1 million significantly exceed current assets of $1.1 million. Total equity stands at $6.1 million, while long-term debt is minimal at $0.1 million, resulting in a debt-to-equity ratio of 0.02. However, the company faces substantial doubt about its ability to continue as a going concern, as explicitly noted in recent filings. Return on equity is -67.7% and return on assets is -45.1%, reflecting severe profitability challenges relative to any standard industry benchmark.
Profitability remains deeply negative, with a net loss of $2.4 million in Q1 2026 against revenue of only $0.3 million. The gross profit of $55,000 yields a gross margin of approximately 17.4%, which is insufficient to cover operating expenses, leading to an operating loss of $2.5 million. Free cash flow is negative at -$1.2 million, driven by operating cash outflows of -$1.2 million and minimal capital expenditures of $1,000. The company’s valuation metrics are distorted by its small market cap of $27.7 million and negative earnings, resulting in a negative EV/EBITDA of -3.72 and a high EV/Revenue of 31.74.
IGC Pharma, Inc. (IGC) has undergone a comprehensive revision of its AI-driven analytical profile, with significant updates to its business summary, narrative, and key takeaways. The most material change involves a 30.58% increase in the company's calculated market share percentage, which rose from approximately 4.51e-09 to 5.89e-09. This adjustment, alongside the removal of eight key takeaways and the addition of one, reflects a substantial recalibration of the firm's strategic positioning and operational outlook within the analysis framework. These modifications stem from a medium-severity update sourced from the "ha_light_thesis," which triggered a complete overhaul of the analytical conclusion and supporting narratives. The low similarity scores between the old and new narratives (0.041) and business summaries (0.103) indicate that the underlying assumptions or data inputs driving the analysis have shifted significantly, rather than representing minor incremental adjustments. Despite these analytical shifts, the fundamental structural metrics of IGC Pharma remain static. The company continues to operate with a single officer and maintains zero analyst coverage and no index memberships. Additionally, the shareholder base remains concentrated, with nine top holders identified, suggesting that the recent analytical changes have not yet translated into broader institutional engagement or structural corporate changes. The significance of these changes lies in the refined understanding of IGC's market position, even as its absolute market share remains negligible. The updated analysis provides a more current view of the company's business dynamics, which is critical for stakeholders monitoring a firm with limited public financial scrutiny. As the company continues to report through its standard regulatory filings, these analytical updates serve as the primary indicator of evolving internal or external perceptions of its value proposition.
- IGC Pharma faces a severe liquidity crisis with a current ratio of 0.4 and a going-concern warning in its filings.
- The company is burning cash rapidly, with Q1 2026 free cash flow at -$1.2 million and cash reserves dropping to $207,000.
- Dilution is a key risk, with shares outstanding increasing by 3.8 million in Q1 2026 through equity offerings.
- Profitability is deeply negative, with a net loss of $2.4 million against minimal revenue of $0.3 million.
- The company relies on external financing, including loans and stock issuances, to fund operations and development.
Bull / Bear case
Generated · model-assistedThe company maintains a low debt-to-equity ratio of 0.02, indicating minimal leverage risk compared to the pharmaceutical cohort median.
Cash conversion efficiency of 1.14 exceeds the cohort median of 0.95, suggesting superior operational cash generation relative to peers.
Revenue grew 42.9% year-over-year in the latest period, demonstrating significant top-line expansion momentum despite profitability challenges.
The company faces high liquidity risk and medium dilution risk, threatening capital stability and existing shareholder value preservation.
Operating margin of -8.9% places the company in the bottom quartile among 819 pharmaceutical peers, indicating poor operational efficiency.
In focus — financials by report
Revenue $317.0k; Operating income -$2.5M.
- ▍Revenue $317.0k
- ▍Operating income -$2.5M
- ▍Net margin -757.7%
Revenue $519.0k; Operating income -$4.8M.
- ▍Revenue $519.0k
- ▍Operating income -$4.8M
- ▍Net margin -659.0%
Revenue $328.0k; Operating income -$1.9M.
- ▍Revenue $328.0k
- ▍Operating income -$1.9M
- ▍Net margin -487.5%
Revenue $869.0k; Operating income -$7.7M.
- ▍Revenue $869.0k
- ▍Operating income -$7.7M
- ▍Net margin -477.1%
Revenue $1.3M; Operating income -$7.4M.
- ▍Revenue $1.3M
- ▍Operating income -$7.4M
- ▍Net margin -560.3%
Revenue $941.0k; Operating income -$6.0M.
- ▍Revenue $941.0k
- ▍Operating income -$6.0M
- ▍Net margin -627.0%
Revenue $1.3M; Operating income -$9.8M.
- ▍Revenue $1.3M
- ▍Operating income -$9.8M
- ▍Net margin -966.5%
Revenue $1.3M; Operating income -$9.8M.
- ▍Revenue $1.3M
- ▍Operating income -$9.8M
- ▍Net margin -966.5%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,08 |
| Revenue | —no estimate | —no estimate | 910,000 USD |
| Operating income | —no estimate | —no estimate | -8,6M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Current liabilities exceed current assets.
- Filings reference going-concern or substantial-doubt language.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director, CEO · Options → Common StockDisposed 323 077 @ $0,26exercise · 2026-04-01
- Director, CEO · Restricted Stock Units → Common StockDisposed 16 667exercise · 2026-04-01
- Director, CEO · Restricted Stock Units → Common StockDisposed 33 332exercise · 2026-04-01
- Director · Restricted Stock Units → Common StockDisposed 70 000exercise · 2026-04-01
- Director · Restricted Stock Units → Common StockDisposed 80 000exercise · 2026-04-01
- Director · Restricted Stock Units → Common StockDisposed 100 000exercise · 2026-04-01
- Director, CEO · Restricted Stock Units → Common StockDisposed 333 333exercise · 2026-04-01
- Director, PFO · Restricted Stock Units → Common StockDisposed 100 000exercise · 2026-04-01
- Director, PFO · Options → Common StockDisposed 138 462 @ $0,26exercise · 2026-04-01
- Director · Restricted Stock Units → Common StockDisposed 50 000exercise · 2026-04-01
- Director, CEO · Restricted Stock Units → Common StockAcquired 16 667grant · 2026-02-03
- Director, CEO · Restricted Stock Units → Common StockAcquired 66 666grant · 2026-02-03
- Director · Restricted Stock Units → Common StockDisposed 100 000exercise · 2026-01-19
- Director, CEO · Options → Common StockAcquired 1 500 000grant · 2025-10-17
- Director · Options → Common StockAcquired 750 000grant · 2025-10-17
- Director · Options → Common StockAcquired 500 000grant · 2025-10-17
- Director · Options → Common StockAcquired 500 000grant · 2025-10-17
- Director, PFO · Options → Common StockAcquired 1 000 000grant · 2025-10-17
- Director, PFO · Options → Common StockAcquired 500 000grant · 2025-10-17
- Director, CEO · Options → Common StockAcquired 3 000 000grant · 2025-10-17
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Enterprise Valuemarket_cap - net_cash
- Return On Assetsnet_income / total_assets
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- IGC Pharma, Inc. company facts · 2026-07-07
- IGC Pharma, Inc. 10-Q 2026-05-15 · 2026-07-07
- IGC Pharma, Inc. 10-Q 2025-11-14 · 2026-07-07
- IGC Pharma, Inc. 10-Q 2025-08-14 · 2026-07-07
- IGC Pharma, Inc. 10-K 2025-06-27 · 2026-07-07
- 8-K (sec_8k_material) on IGC · 2026-07-07
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Ram MukundaPresident, Chief Executive Officer, Director
Insider activity
- Director, CEO · Common StockOther 2 226 475 @ $0,27$601K · 2026-06-30
- Director, PFO · Common StockOther 2 048 378 @ $0,27$553K · 2026-06-30
- Director, CEO · Common StockOther 333 333 · 2026-04-01
- Director · Common StockOther 100 000 · 2026-04-01
- Director, PFO · Common StockOther 138 462 @ $0,26$36K · 2026-04-01
- Director, PFO · Common StockOther 100 000 · 2026-04-01
- Director · Common StockOther 50 000 · 2026-04-01
- Director · Common StockOther 80 000 · 2026-04-01
- Director, CEO · Common StockOther 33 332 · 2026-04-01
- Director, CEO · Common StockOther 16 667 · 2026-04-01
- Director, CEO · Common StockOther 323 077 @ $0,26$84K · 2026-04-01
- Director · Common StockOther 70 000 · 2026-04-01
- Director, CEO · Common StockOther 50 000 · 2026-02-03
- Director · Common StockOther 100 000 · 2026-01-19
- Director, PFO · Common StockOther 50 000 · 2025-10-17
- Director, CEO · Common StockOther 100 000 · 2025-10-17
Short positioning
Geographic breakdown
Intel & risk
no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)
- Narrative— → —medium
- Business summary— → —medium
- Conclusion— → —medium
- Key takeaways— → —medium
- Company share pct— → —medium
Evidence & claims
From filings & derived data- Debt-to-equity (FY 2025-12-31): 0.31xDerived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -2.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -18.8%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 91.5%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.83xDerived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 18.6%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 7.0%Derived (calculated)
- Shares outstanding (annual): 95.04MSEC XBRL filing
- Total assets (annual): USD 9.71MSEC XBRL filing
- Current assets (annual): USD 1.79MSEC XBRL filing
- Long-term debt (annual): USD 131KSEC XBRL filing
- Shareholders' equity (annual): USD 7.42MSEC XBRL filing
- Current liabilities (annual): USD 2.16MSEC XBRL filing
- Total liabilities (annual): USD 2.29MSEC XBRL filing
- Cash & equivalents (annual): USD 900KSEC XBRL filing
- Revenue (YoY) (2025-03-31 vs 2024-03-31): -5.5%Derived (calculated)
- Net income (YoY) (2025-03-31 vs 2024-03-31): 45.2%Derived (calculated)
- Capex (YoY) (2025-03-31 vs 2024-03-31): -18.8%Derived (calculated)
- EPS (diluted) (YoY) (2025-03-31 vs 2024-03-31): 59.1%Derived (calculated)
- EPS (basic) (YoY) (2025-03-31 vs 2024-03-31): 59.1%Derived (calculated)
- Gross profit (YoY) (2025-03-31 vs 2024-03-31): -15.6%Derived (calculated)
- Cost of revenue (YoY) (2025-03-31 vs 2024-03-31): 6.5%Derived (calculated)
- R&D expense (YoY) (2025-03-31 vs 2024-03-31): -3.1%Derived (calculated)
- Net margin (FY 2025-03-31): -560.3%Derived (calculated)